Evidence map›Paper›PMID 32783920›Full record

ArticleImmunity2020

Distinct Early Serological Signatures Track with SARS-CoV-2 Survival.

Caroline Atyeo, Stephanie Fischinger, Tomer Zohar, Matthew D Slein, John Burke, Carolin Loos, Denise J McCulloch, Kira L Newman, Caitlin Wolf, Jingyou Yu and 14 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 250 papers.

0numbers the graph read from it
0cells of the map it votes in
250citing papers in PubMed
8.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

250 citing papers in PubMed, 417 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

190 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 7 institutions in 2 countries.

Caroline AtyeoRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA; PhD Program in Virology, Division of Medical Sciences, Harvard University, Boston, MA, USA.
Stephanie FischingerRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA; PhD Program in Immunology and Virology, University of Duisburg-Essen, Essen, Germany.
Tomer ZoharRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
Matthew D SleinRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
John BurkeRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Carolin LoosRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
Denise J McCullochDepartment of Medicine, University of Washington, Seattle, WA, USA.
Kira L NewmanDepartment of Medicine, University of Washington, Seattle, WA, USA.
Caitlin WolfDepartment of Medicine, University of Washington, Seattle, WA, USA.
Jingyou YuCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Kiel ShueyDepartment of Medicine, University of Washington, Seattle, WA, USA.
Jared FeldmanRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Blake Marie HauserRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Tim CaradonnaRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Aaron G SchmidtRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Todd J SuscovichSeromYx Systems, Cambridge, MA, USA.
Caitlyn LindeSeromYx Systems, Cambridge, MA, USA.
Yongfei CaiDivision of Molecular Medicine, Boston Children's Hospital, and Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
Dan BarouchCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Edward T RyanInfectious Disease Division, Massachusetts General Hospital, Boston, MA, USA.
Richelle C CharlesInfectious Disease Division, Massachusetts General Hospital, Boston, MA, USA.
Douglas LauffenburgerDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
Helen ChuDepartment of Medicine, University of Washington, Seattle, WA, USA. Electronic address: helenchu@uw.edu.
Galit AlterRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA. Electronic address: galter@partners.org.
Ragon Institute of MGH, MIT and Harvard · USUniversity of Washington · USBeth Israel Deaconess Medical Center · USMassachusetts General Hospital · USBoston Children's Hospital · USHarvard University · USMassachusetts Institute of Technology · US

Funding

Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0M
Technology CoreU19AI135995 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Bryan Briney · 2018 to 2026
$32.0M
HOST DEFENSE TRAINING IN ALLERGY AND INFECTIOUS DISEASEST32AI007044 · NIAID · UNIVERSITY OF WASHINGTON · PI DAVID Neal FREDRICKS · 1985 to 2026
$14.6M
Epitope focusing to the receptor binding motif for a universal coronavirus vaccineR01AI146779 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI SCHMIDT, AARON GREGORY · 2019 to 2023
$4.2M
ACL HHS U01CK000490NCEZID CDC HHS U01 CK000490NIAID NIH HHS R01 AI146779NIAID NIH HHS T32 AI007044NIAID NIH HHS U19 AI135995NIGMS NIH HHS T32 GM007753
6 · The paper itself

Abstract

As SARS-CoV-2 infections and death counts continue to rise, it remains unclear why some individuals recover from infection, whereas others rapidly progress and die. Although the immunological mechanisms that underlie different clinical trajectories remain poorly defined, pathogen-specific antibodies often point to immunological mechanisms of protection. Here, we profiled SARS-CoV-2-specific humoral responses in a cohort of 22 hospitalized individuals. Despite inter-individual heterogeneity, distinct antibody signatures resolved individuals with different outcomes. Although no differences in SARS-CoV-2-specific IgG levels were observed, spike-specific humoral responses were enriched among convalescent individuals, whereas functional antibody responses to the nucleocapsid were elevated in deceased individuals. Furthermore, this enriched immunodominant spike-specific antibody profile in convalescents was confirmed in a larger validation cohort. These results demonstrate that early antigen-specific and qualitative features of SARS-CoV-2-specific antibodies point to differences in disease trajectory, highlighting the potential importance of functional antigen-specific humoral immunity to guide patient care and vaccine development.

Indexed as

AdultAgedAged, 80 and overAntibodies, ViralBetacoronavirusCoronavirus InfectionsCoronavirus Nucleocapsid ProteinsCOVID-19FemaleHumansImmunity, HumoralImmunoglobulin GMaleMiddle AgedNucleocapsid ProteinsPandemicsAntibodies, ViralCoronavirus Nucleocapsid ProteinsImmunoglobulin Gnucleocapsid phosphoprotein, SARS-CoV-2Nucleocapsid ProteinsPhosphoproteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2COVID-19 patientsfunctional antibodySARS-CoV-2SARS-CoV-2-specific antibody

Identifiers

PMID32783920
PMCPMC7392190
OpenAlexW3045933491

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.